IGHV3-66*01 (81.4%) -(IGHD) -IGHJ1*01 (100%), CDR-IMGT [8.7.6] (26-33.51-57.96-101)) (1-112) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14, 8-G1v29 CH2 A84.4 (CH1 R120>K (209) (113-210), hinge 1-15 (211-225), CH2 N84.4>A (292) (226-335), CH3 E12 (351), M14 (353) (336-440), CHS (441-442)) (113-442)], (215-216')-disulfide with L-kappa light chain humanized (1'-216') [V-KAPPA (Homo sapiens IGKV1-5*01 (85.4%) -IGKJ1*01 (90.0%) Q120>G (102'), CDR-IMGT [7.3.10] (27'-33'.51'-53'.90'-99')) (1'-109') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (155'), V101 (193')) (110'-216')]; dimer (221-221'':224-224'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-DG44, non-glycosylated
Migraine
H. Lundbeck A/Smonoclonal_antibodyPhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 73/ 100
Competitive context
106 Active assets in the Migraine cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Atogepant Stanford University | Phase 4 | A |
Rizatriptan Antonios Likourezos | Phase 4 | A |
Naproxen IRCCS San Raffaele Roma | Phase 4 | A |
Zolmitriptan Zosano Pharma Corporation | Phase 4 | A |
Treximet® IRCCS San Raffaele Roma | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →